Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Systematic Review Article

Effect of Botulinum Toxin on Equinus Foot Deformity in Cerebral Palsy Patients: A Systematic Review and Network Meta-analysis

Author(s): Mohamed Fathi*, Ahmed S. Hussein, Shrouk M.Elghazaly, Asmaa M. Al-Kinawy, Ahmed K. Abdeltawab, Yasmin M. Mansour, Nada A. Elbehbeh, Ahmed Sherif and Ahmed M. Afifi

Volume 26 , Issue 37 , 2020

Page: [4796 - 4807] Pages: 12

DOI: 10.2174/1381612826666200518105633

Price: $65

Abstract

Background: Cerebral palsy (CP) is a brain disorder that affects the development, movement and posture leading to limitation of Range of Movement (ROM) in the growing children. CP leads to deformities such as equinus foot deformity. We aim to investigate the efficacy of different botulinum toxin (BTX) products with or without serial casting in reducing the muscle spasticity in equinus foot deformity in patients with CP.

Methods: A systematic review of the literature was performed by searching different electronic databases. Pub- Med, Scopus, Web of Science (WOS), and GHL databases were used. We analyzed the extracted data by network meta-analysis method using the R software package (version 3.5.0).

Results: Regarding Modified Ashworth score (MAS), BTX-A was superior compared to placebo and BTX-A plus immediate casting (MD = −0.39, 95% CI [−0.60; −0.18]) and (MD = −0.50, 95% CI [−0.98; −0.02]), respectively. Concerning growth motor function movement Classification System (GMFM), Neuronox ranked above at 3 months (MD = −1.60, 95% CI [−2.87; −0.33]) and at six months (MD = −1.90, 95% CI [−3.48; −0.32]) compared to BTX-A. Regarding the Modified Tardieu scale (MTS) with knee flexion, BTX-A was superior to BTX-A plus immediate casting (MD = 8.60, 95% CI [1.76; 15.44]). Concerning passive range of movement (PROM) with Knee flexion or extension at 3 months, BTX-A showed a significant improvement compared to BTX-A plus immediate casting.

Conclusion: BTX-A ranked best on a physician rating scale (PRS), MAS, MTS with knee flexion and PROM (Knee flexion and extension) compared to Neuronox and Botulax. BTX-A alone was also better than BTX-A plus immediate casting.

Keywords: Botulinum, spasticity, cerebral palsy, equinus deformity, physician rating scale, Knee flexion and extension.

[1]
Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8-14.
[PMID: 17370477]
[2]
Arneson CL, Durkin MS, Benedict RE, et al. Prevalence of cerebral palsy: Autism and Developmental Disabilities Monitoring Network, three sites, United States, 2004. Disabil Health J 2009; 2(1): 45-8.
[http://dx.doi.org/10.1016/j.dhjo.2008.08.001 ] [PMID: 21122742]
[3]
Winter S, Autry A, Boyle C, Yeargin-Allsopp M. Trends in the prevalence of cerebral palsy in a population-based study. Pediatrics 2002; 110(6): 1220-5.
[http://dx.doi.org/10.1542/peds.110.6.1220 ] [PMID: 12456922]
[4]
Christensen D, Van Naarden Braun K, Doernberg NS, et al. Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning - Autism and Developmental Disabilities Monitoring Network, USA, 2008. Dev Med Child Neurol 2014; 56(1): 59-65.
[http://dx.doi.org/10.1111/dmcn.12268 ] [PMID: 24117446]
[5]
Graham HK. Botulinum toxin A in cerebral palsy: functional outcomes. J Pediatr 2000; 137(3): 300-3.
[http://dx.doi.org/10.1067/mpd.2000.109107 ] [PMID: 10969251]
[6]
Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW. Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003; 111(1): e89-97.
[http://dx.doi.org/10.1542/peds.111.1.e89 ] [PMID: 12509602]
[7]
Shamsoddini A, Amirsalari S, Hollisaz MT, Rahimnia A, Khatibi-Aghda A. Management of spasticity in children with cerebral palsy. Iran J Pediatr 2014; 24(4): 345-51.
[PMID: 25755853]
[8]
S A. The efficacy of botulinum toxin type A injection in the hamstring and calf muscles with and without serial foot casting in gait improvement in children with cerebral palsy. Tehran Univ Med J 2011; 69: 509-17.
[9]
Tilton AH. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol 2004; 11(1): 58-65.
[http://dx.doi.org/10.1016/j.spen.2004.01.008 ] [PMID: 15132254]
[10]
Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol 2010; 55(1): 8-14.
[http://dx.doi.org/10.4103/0019-5154.60343 ] [PMID: 20418969]
[11]
Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002; 18(6)(Suppl.): S142-6.
[http://dx.doi.org/10.1097/00002508-200211001-00005 ] [PMID: 12569961]
[12]
Orsini M, Leite MA, Chung TM, et al. Botulinum Neurotoxin Type A in Neurology: Update. Neurol Int 2015; 7(2): 5886.
[http://dx.doi.org/10.4081/ni.2015.5886 ] [PMID: 26487928]
[13]
Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawicki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in children with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev 2010; (1): CD003469
[http://dx.doi.org/10.1002/14651858.CD003469.pub4 ] [PMID: 20091546]
[14]
Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J. Network meta-analysis using R: a review of currently available automated packages. PLoS One 2014; 9(12) e115065
[http://dx.doi.org/10.1371/journal.pone.0115065 ] [PMID: 25541687]
[15]
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. J Multidiciplinary Eval 2010; 6(14): 142-8.
[http://dx.doi.org/10.1002/9780470712184]
[16]
Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am 2006; 88(1): 161-70.
[PMID: 16391261]
[17]
Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006; 13(Suppl. 1): 2-10.
[http://dx.doi.org/10.1111/j.1468-1331.2006.01438.x ] [PMID: 16417591]
[18]
Glanzman AM, Kim H, Swaminathan K, Beck T. Efficacy of botulinum toxin A, serial casting, and combined treatment for spastic equinus: a retrospective analysis. Dev Med Child Neurol 2004; 46(12): 807-11.
[http://dx.doi.org/10.1111/j.1469-8749.2004.tb00445.x ] [PMID: 15581153]
[19]
Kaushik PS, Gowda VK, Shivappa SK, Mannapur R, Jaysheel A. A Randomized Control Trial of Botulinum Toxin A Administration under Ultrasound Guidance against Manual Palpation in Spastic Cerebral Palsy. J Pediatr Neurosci 2018; 13(4): 443-7.
[http://dx.doi.org/10.4103/JPN.JPN_60_18 ] [PMID: 30937086]
[20]
Jain S, Mathur N, Joshi M, Jindal R, Goenka S. Effect of serial casting in spastic cerebral palsy. Indian J Pediatr 2008; 75(10): 997-1002.
[http://dx.doi.org/10.1007/s12098-008-0100-z ] [PMID: 18574577]
[21]
Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics 2016; 137(2) e20152830
[http://dx.doi.org/10.1542/peds.2015-2830 ] [PMID: 26812925]
[22]
Park ES, Rha DW, Yoo JK, Kim SM, Chang WH, Song SH. Short-term effects of combined serial casting and botulinum toxin injection for spastic equinus in ambulatory children with cerebral palsy. Yonsei Med J 2010; 51(4): 579-84.
[http://dx.doi.org/10.3349/ymj.2010.51.4.579 ] [PMID: 20499426]
[23]
Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol 2011; 53(3): 239-44.
[http://dx.doi.org/10.1111/j.1469-8749.2010.03830.x ] [PMID: 21087238]
[24]
Chang HJ, Hong BY, Lee S-J, Lee S, Park JH, Kwon J-Y. Efficacy and safety of letibotulinum toxin a for the treatment of dynamic equinus foot deformity in children with cerebral palsy: A randomized controlled trial. Toxins (Basel) 2017; 9(8): 252.
[http://dx.doi.org/10.3390/toxins9080252 ] [PMID: 28820439]
[25]
Kay RM, Rethlefsen SA, Fern-Buneo A, Wren TA, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. J Bone Joint Surg Am 2004; 86(11): 2377-84.
[http://dx.doi.org/10.2106/00004623-200411000-00003 ] [PMID: 15523006]
[26]
Ackman JD, Russman BS, Thomas SS, Buckon CE, Sussman MD, et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 2005; 47(9): 620-7.
[http://dx.doi.org/10.1111/j.1469-8749.2005.tb01215.x ] [PMID: 16138670]
[27]
Newman CJ, Kennedy A, Walsh M, O’Brien T, Lynch B, Hensey O. A pilot study of delayed versus immediate serial casting after botulinum toxin injection for partially reducible spastic equinus. J Pediatr Orthop 2007; 27(8): 882-5.
[http://dx.doi.org/10.1097/BPO.0b013e31815b4d7d ] [PMID: 18209608]
[28]
Manganotti P, Zaina F, Falso M, Milanese F, Fiaschi A. Evaluation of botulinum toxin therapy of spastic equinus in paediatric patients with cerebral palsy. J Rehabil Med 2007; 39(2): 115-20.
[http://dx.doi.org/10.2340/16501977-0036 ] [PMID: 17351692]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy